Ikonisys Receives FDA Clearance For Non-Invasive, HER-2 Breast Cancer Test

Ikonisys, a leading provider of next generation, non-invasive, cell-based diagnostic solutions, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its oncoFISH her2 test. oncoFISH her2 is a fully automated microscopy application for the determination of HER2 status in human breast cancer specimens processed with Abbott’s PathVysion® HER2 DNA Probe Kit.

More: continued here

Filed under: Breast Cancer on October 29th, 2008